Eye Health Supplements: What the Evidence Shows

Five different conditions, five different evidence bases

The most pervasive problem in eye supplement marketing is collapsing five distinct clinical conditions into a single 'eye health' concept. The research for each is separate, the mechanisms differ, and what works for one does not work for the others.

Age-Related Macular Degeneration (AMD) is progressive central vision loss caused by deterioration of the macula — the central part of the retina responsible for fine detail and colour. It is the leading cause of vision loss in adults over 50 in the developed world. AMD is the primary target of most eye supplement research, and the AREDS2 trial is the definitive intervention study.

Dry eye disease is a chronic condition of insufficient tear volume or quality, causing surface irritation, photophobia, and blurred vision. It is inflammatory in mechanism, not retinal. Omega-3 fatty acids have been studied for dry eye specifically.

Glaucoma is optic nerve damage, most commonly associated with elevated intraocular pressure. It is managed medically with eye drops or surgically — not with supplements. The one ingredient with any meaningful glaucoma-specific evidence is ginkgo biloba, and only for the rarer normal tension subtype.

Cataracts are clouding of the lens — primarily a surgical problem. No supplement has credibly demonstrated ability to prevent or reverse cataracts in large controlled trials despite decades of antioxidant research.

Digital eye strain and visual fatigue are functional symptoms of prolonged screen use — accommodation difficulty, dry surface, and visual discomfort — not structural damage. This is the one area where supplements for healthy adults have the most plausible clinical rationale.

The AREDS2 problem: who the research actually applies to

The AREDS2 trial is the most important clinical study in the eye supplement space, and it is routinely misrepresented in marketing. Understanding exactly what it found — and who it applies to — is the single most important thing to know before buying any eye supplement.

AREDS2 was a National Institutes of Health-funded randomised controlled trial published in JAMA in 2013. It enrolled 4,203 participants and followed them for a median of five years. The participants all had either intermediate AMD (bilateral large drusen or pigmentary changes) or advanced AMD in one eye. They were not healthy adults. They were patients under ophthalmological care with confirmed, staged AMD.

The finding: the AREDS2 formula (vitamin C 500mg, vitamin E 400IU, lutein 10mg, zeaxanthin 2mg, zinc 80mg, copper 2mg) reduced the risk of progression to advanced AMD by approximately 25% over five years compared to placebo. This is a meaningful clinical result for the people it studied.

What AREDS2 did not show: it did not show that this formula prevents AMD in people who do not yet have intermediate AMD. It did not show that it restores lost vision. It did not show benefit for people with no AMD or early AMD (small drusen only). The American Academy of Ophthalmology recommends the AREDS2 formula specifically for intermediate and advanced AMD — not as a general supplement for healthy adults.

The implication: products marketed as 'AREDS2-inspired' or 'AREDS2 formula' to the general public are using research conducted in a specific diagnosed patient population to justify sales to people who are not that population and for whom no clinical benefit has been demonstrated.

Ingredients ranked by evidence strength

The table below covers the main ingredients in this category. Evidence tiers reflect the quality and consistency of human clinical trial data. The condition column matters — an ingredient with strong AMD evidence has no proven benefit for dry eye or cataracts, and vice versa.

The beta-carotene safety issue

The original AREDS formula (AREDS1, 2001) included beta-carotene 15mg as an antioxidant. AREDS2 was designed in part to determine whether beta-carotene could safely be replaced — and the answer was yes, with lutein and zeaxanthin showing equivalent AMD benefit without the lung cancer risk.

The CARET trial (NEJM, 1996) enrolled 18,314 people at high lung cancer risk — smokers, former smokers, and asbestos-exposed workers — and randomised them to high-dose beta-carotene plus vitamin A or placebo. The trial was stopped early when interim analysis showed beta-carotene was causing harm: a statistically significant 28% increase in lung cancer incidence and 17% increase in overall mortality.

The ATBC trial (NEJM, 1994), a Finnish study of 29,133 male smokers, found similar results: beta-carotene supplementation increased lung cancer incidence by 18%.

These are not small observational signals — they are findings from two large, rigorous randomised controlled trials. The AREDS2 research group explicitly cited these findings when redesigning the formula to use lutein and zeaxanthin instead.

Any eye supplement still formulated with beta-carotene rather than lutein/zeaxanthin is using the outdated AREDS1 template that was superseded precisely because of this safety issue. For current or former smokers in particular, beta-carotene-containing eye supplements are potentially harmful.

Safety concerns specific to this category

• Beta-carotene in smokers and former smokers — see the dedicated section above; two large RCTs show significantly increased lung cancer risk; any eye supplement with beta-carotene should be avoided by anyone with smoking history
• High-dose zinc (80mg/day) and copper depletion — the AREDS2 dose of zinc is approximately 7x the adult RDA. Long-term use depletes copper through competitive absorption, causing hypocupremia: peripheral neuropathy, spinal cord damage, and sideroblastic anemia. AREDS2 protocol includes 2mg copper precisely for this reason. Taking high-dose zinc supplements without the copper component is a genuine risk
• High-dose zinc (80mg/day) gastrointestinal effects — nausea, cramping, and GI upset are common at AREDS zinc doses; this is why AREDS2 tested a lower-dose zinc arm (25mg) and found comparable benefit with better tolerability
• Vitamin E at high doses — AREDS includes vitamin E 400 IU. The SELECT trial (prostate cancer prevention) showed 400 IU alpha-tocopherol/day increased prostate cancer incidence by 17% in healthy men. The AREDS vitamin E dose is within a studied context; general use of high-dose vitamin E supplements without AMD indication is not supported and carries risk signals
• Ginkgo biloba and anticoagulant interactions — ginkgo has meaningful anti-platelet effects. Clinically significant interaction with warfarin, clopidogrel, aspirin, and NSAIDs. Relevant to older AMD patients who are also commonly on anticoagulant therapy; disclose all supplements to your prescriber
• Fat-soluble vitamin accumulation — vitamins A, D, E, and K are fat-soluble and accumulate in body fat rather than being excreted. Chronic high-dose supplementation of fat-soluble vitamins can cause toxicity; relevant to people who take multiple supplements simultaneously (an eye formula, a multivitamin, and a fish oil, for example, may combine to create unexpectedly high vitamin E intake)

Red flags specific to this category

• "Restores vision" or "reverses vision loss" — no supplement has demonstrated this in any adequately powered clinical trial; the AREDS2 result is risk reduction for diagnosed AMD, not vision restoration
• "Improves vision" in healthy adults — this claim is not supported by the AREDS2 evidence, which applied only to people with diagnosed intermediate or advanced AMD; in undiagnosed healthy adults, no well-powered RCT shows measurable vision improvement
• "AREDS2 formula" marketed to general audiences — AREDS2 showed no benefit for people without intermediate or advanced AMD; marketing the formula to general 'eye health' buyers misrepresents the population the research applied to
• Beta-carotene still in the formula — this is the older AREDS1 formulation that was explicitly superseded in 2013 due to the lung cancer risk in smokers; any product still using beta-carotene instead of lutein/zeaxanthin has not updated to the current evidence standard
• Night vision improvement claims — bilberry and vitamin A are commonly marketed for night vision; bilberry has a Cochrane-level null result in healthy adults, and vitamin A only helps people who are actually deficient (uncommon in developed countries)
• Claiming to address AMD, glaucoma, cataracts, and dry eye simultaneously — these are mechanistically distinct conditions; no single formula is optimised for all four, and marketing across all of them suggests the product is targeting marketing language rather than clinical mechanisms
• No individual ingredient doses listed — AREDS2 is specific: lutein 10mg, zeaxanthin 2mg, vitamin C 500mg, vitamin E 400IU, zinc 80mg, copper 2mg; a formula that claims AREDS2 compliance without disclosing individual doses cannot be verified
• Vision supplements sold as part of gut health or detox protocols — we reviewed products whose eye supplement formula was primarily digestive enzymes and probiotics; the gut-eye axis is a real research area but has not produced any supplement with demonstrated AMD or vision benefit
• Fabricated clinical backing — products in adjacent categories have used fictional endorsers, manufactured research citations, and deepfake physician endorsements; the supplement industry has no pre-market approval requirement, making identity verification claims impossible to confirm